← Patent-cliff monitor Loss of exclusivity December 2040 latest FDA-listed patent expiry
Drug detail Brand name OJJAARA Active ingredient MOMELOTINIB DIHYDROCHLORIDE Strength EQ 100MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2023 Marketing status RX
Listed patents Patent Expires Type 11963962 December 2040 use U-3928 12576089 August 2039 use U-4441 9809559 June 2035 use U-1201 RE48285 June 2035 substance, product 8486941 January 2035 substance, product
Regulatory exclusivity Code Expires ODE-441 September 2030 NCE September 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.